Recon: BioNTech buys production site, T-cell platform from Gilead; China approves AstraZeneca’s Imfinzi for aggressive form of lung cancer
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy